Pfizer appoints Albert Bourla as COO
Dr. Bourla has been the Group President of Pfizer’s Innovative Health Business since the beginning of 2016.
Prior to his current position Dr. Bourla was the Group President for Pfizer’s Vaccines, Oncology and Consumer Healthcare businesses where he was instrumental in building a strong and competitive position in Oncology and expanded the company’s leadership in vaccines.
Over the course of his career he has held a number of senior global positions across a range of businesses and geographies.
Prior to leading the Established Products business, Dr. Bourla was the Area President for Pfizer’s Animal Health business across Europe, Africa, and Asia Pacific where he successfully managed the integration of Wyeth’s Animal Health Business (Fort Dodge) with Pfizer in these global markets.
Dr. Bourla has significant scientific expertise. ■